Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | UBE2N | P61088 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25408807 | 1.00 | CMA1 (0.46) | CMA1ALDH1A1POLBHTR6KMT2A | |
| SCHEMBL25411450 | 0.92 | ALDH1A1 (0.40) | CMA1ALDH1A1KDM4EUBE2NLMNA | |
| SCHEMBL25411441 | 0.92 | ALDH1A1 (0.40) | CMA1ALDH1A1KDM4EUBE2NLMNA | |
| SCHEMBL25413834 | 0.92 | KDM4E (0.39) | CMA1ALDH1A1HTR6KDM4EUBE2N | |
| SCHEMBL25413830 | 0.92 | KDM4E (0.39) | CMA1ALDH1A1HTR6KDM4EUBE2N | |
| SCHEMBL25413763 | 0.91 | ALDH1A1 (0.38) | CMA1ALDH1A1POLBKDM4EUBE2N | |
| SCHEMBL25413769 | 0.91 | ALDH1A1 (0.38) | CMA1ALDH1A1POLBKDM4EUBE2N | |
| SCHEMBL25410654 | 0.89 | PKM (0.43) | CMA1ALDH1A1POLBHTR6KMT2A | |
| SCHEMBL25410650 | 0.89 | PKM (0.43) | CMA1ALDH1A1POLBHTR6KMT2A | |
| SCHEMBL25412765 | 0.89 | GAA (0.44) | CMA1ALDH1A1POLBKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278959-A1 | Synthesis of Optically Active Indoline Derivatives Via Ruthenium(II)-Catalyzed Enantioselective C-H Functionalization | MISSISSIPPI STATE UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230278959-A1 | Synthesis of Optically Active Indoline Derivatives Via Ruthenium(II)-Catalyzed Enantioselective C-H Functionalization | MISSISSIPPI STATE UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278959-A1 | Synthesis of Optically Active Indoline Derivatives Via Ruthenium(II)-Catalyzed Enantioselective C-H Functionalization | INMT, IDO2, WEE2 | CMA1 1751/4885ALDH1A1 3453/4885POLB 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.